ArticleInfection and drug resistance2026
Clinical and Microbiological Characteristics Associated with Treatment Outcomes Among Rifampicin-Resistant Tuberculosis Patients in Limpopo Province.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (DR-TB) remains a major public health concern in South Africa, particularly in rural provinces such as Limpopo, where access to specialized care is limited. High HIV prevalence, population mobility, and constrained diagnostic capacity further complicate disease control. Province-specific data are essential to guide targeted interventions; however, factors associated with treatment outcomes in rural settings remain poorly characterized. Methods: A retrospective cohort study was conducted using routinely collected laboratory and programmatic data. All laboratory-confirmed DR-TB cases recorded in Limpopo Province between 2023 and 2025 were included. Microbiological data were obtained from the National Health Laboratory Service, while demographic, clinical, and treatment outcome data were extracted from the Electronic Drug-Resistant Tuberculosis Register. Descriptive statistics summarized patient characteristics. Associations with treatment outcomes were assessed using chi-square tests and multivariable logistic regression. Kaplan-Meier analysis compared survival by HIV status. Results: A total of 86 RR-TB patients were included. Most were aged 25-44 years (65.1%), with males comprising 70.9%, and 55.8% were HIV co-infected. Favourable treatment outcomes were observed in 62 (71.4%) patients, while 12 (14.3%) experienced unfavourable outcomes and 12 (14.3%) remained on treatment. In multivariable analysis, younger age (15-24 years) (AOR = 9.97, 95% CI: 1.48-67.33) and smear-negative status (AOR = 39.62, 95% CI: 3.33-471.83) were independently associated with unfavourable outcomes, whereas HIV status was not significant after adjustment. Kaplan-Meier analysis showed poorer survival among HIV-positive patients (log-rank p = 0.002), although this was not retained in the adjusted model. Conclusion: DR-TB in Limpopo is characterized by a high burden of TB-HIV co-infection and rifampicin resistance. Clinical factors, rather than resistance patterns, were key determinants of unfavourable outcomes. Strengthening integrated TB-HIV services, improving early diagnosis, and expanding drug susceptibility testing are critical to improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.